US patent reform 2011: a few things to remember.

Pharm Pat Anal

Vedder Price PC, 1633 Broadway, 47th Floor, New York, NY 10019, USA.

Published: May 2012

Download full-text PDF

Source
http://dx.doi.org/10.4155/ppa.12.11DOI Listing

Publication Analysis

Top Keywords

patent reform
4
reform 2011
4
2011 things
4
things remember
4
patent
1
0
1
things
1
remember
1

Similar Publications

The global aim to move away from fossil fuels requires efficient, inexpensive and sustainable energy storage to fully use renewable energy sources. Thermal energy storage materials in combination with a Carnot battery could revolutionize the energy storage sector. However, a lack of stable, inexpensive and energy-dense thermal energy storage materials impedes the advancement of this technology.

View Article and Find Full Text PDF

Biosimilars and generics have led to reduced cancer drug prices. The effect of biosimilar or generic drug competition on drug manufacturer revenue has not been previously described. In this study, the majority of top selling cancer drugs had a greater than 50 % decline in sales revenue within 2 years of generic or biosimilar market entry, reflecting both the decline in market share and reduction in unit drug price.

View Article and Find Full Text PDF

Gene therapies delivered through a single administration have revolutionized treatment possibilities for many patients living with serious or fatal conditions such as spinal muscular atrophy, hemophilia and sickle cell disease. However, shadowing the excitement about the transformational potential of many gene therapies has been widespread concern about the combination of uncertainty in the durability of their benefits over the long term and the short-term financial shock of high prices. As the healthcare payment ecosystem prepares for the growing number of gene therapies entering the market, three key interconnected challenges must be addressed: determining a fair price, managing clinical uncertainty and managing short-term budget impacts.

View Article and Find Full Text PDF

Physiologists as medical scientists: An early warning from the German academic system.

Physiol Rep

November 2024

Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg · Bad Krozingen, University of Freiburg, Freiburg, Germany.

"Medical scientists" are postgraduate investigators who are engaged in biomedical research, and either hold a biomedical PhD or are qualified in medicine but do not participate in patient care. Medical scientists constitute ~40% of staff at medical faculties and >90% at nonuniversity medical research institutions in Germany. However, medical scientists in Germany face limited long-term career prospects and a lack of dedicated training and support programmes.

View Article and Find Full Text PDF
Article Synopsis
  • * This study introduces a method to improve the stability of these catalysts by anchoring nickel sites within dealuminated Beta zeolite, which enhances metal-support interactions.
  • * Using advanced techniques like X-ray absorption spectroscopy and isotopic experiments, the research explains how the synthesis method increases the performance and durability of the Ni catalysts by reducing unwanted byproducts.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!